New onset diabetes during antihypertensive therapy

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• New onset diabetes (NOD) is prevalent in hypertensive individuals, linked to increased cardiovascular disease (CVD) risk.
• Certain antihypertensives, like thiazide-like diuretics and beta-blockers, are more likely to induce hyperglycemia than renin-angiotensin system blockers or calcium channel blockers.

Purpose of the Study:

• To evaluate the association between NOD induced by antihypertensive medications and subsequent CVD risk.
• To assess the impact of diuretic-induced NOD on CVD outcomes compared to NOD from other antihypertensives.

Main Methods:

• Review of clinical trials and observational studies on antihypertensive drug classes and their association with NOD and CVD.
• Analysis of the impact of blood pressure reduction achieved by diuretics on CVD risk in patients with NOD.

Main Results:

• NOD from diuretic treatment has not been demonstrably linked to increased CVD risk.
• Blood pressure reduction from diuretics may offset the anticipated rise in CVD in patients with NOD.
• NOD can potentially be reversed or managed through electrolyte correction, potassium supplementation, or specific antihypertensive drug additions.

Conclusions:

• Apprehensions about NOD should not dictate initial antihypertensive choices or lead to unnecessary discontinuation of diuretics.
• Diuretic-induced hyperglycemia is manageable and should be tolerated if diuretics are crucial for blood pressure control.
• Aggressive blood pressure management remains paramount in antihypertensive care, even with the consideration of NOD.